MODERATOR
:
D. Michael Strong, PhD, MT(ASCP), Adjunct Professor, Department of Orthopaedics and Sports Medicine, University of Washington, School of Medicine
SPEAKER
(S):
Jerry Holmberg, PhD, MT(ASCP)SBB, Director, Scientific Affairs, Novartis Vaccines and Diagnotstics, Inc.
Matthew Kuehnert, MD, Director, Office of Blood, Organ, Other Tissue Safety, Centers for Disease Control and Prevention
James AuBuchon, MD, FCAP, FRCP (Edin), President & CEO, Puget Sound Blood Center
The US Biovigilance Network - A Public-Private Partnership
Deirdre Fehily, PhD, Inspector and Technical Advisor - Tissues and Cells, Centro Nazionale Trapianti
Vigilance of Substances of Human Origin in the European Union
Description
This session will provide an overview of the U.S. Biovigilance Network, including its history and the development of the public-private partnerships that have been instrumental in the implementation of the two hemovigilance systems launched in 2010. A basic framework will be provided for those looking for an introduction to hemovigilance and biovigilance in the United States and throughout the world.
-
Describe the difference between biovigilance and hemovigilance.
-
List benefits to a hospital for participating in the Hemovigilance Module.
-
List three international hemo/biovigilance systems.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.